Leland Gershell
Stock Analyst at Oppenheimer
(4.57)
# 239
Out of 5,241 analysts
163
Total ratings
51.3%
Success rate
32.67%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERU Veru Inc. | Maintains: Outperform | $25 → $24 | $2.11 | +1,037.44% | 9 | May 15, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $87 → $84 | $34.94 | +140.41% | 9 | May 11, 2026 | |
| URGN UroGen Pharma | Maintains: Outperform | $34 → $40 | $28.26 | +41.54% | 12 | May 7, 2026 | |
| CLYM Climb Bio | Maintains: Outperform | $10 → $18 | $9.65 | +86.53% | 2 | Apr 21, 2026 | |
| ARGX argenx SE | Maintains: Outperform | $1,060 → $1,014 | $797.77 | +27.10% | 8 | Apr 2, 2026 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $110 → $80 | $53.01 | +50.91% | 10 | Mar 18, 2026 | |
| ENGN enGene Therapeutics | Maintains: Outperform | $33 → $30 | $1.53 | +1,860.78% | 4 | Mar 11, 2026 | |
| OCGN Ocugen | Initiates: Outperform | $10 | $1.30 | +669.23% | 1 | Mar 11, 2026 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $125 → $145 | $85.67 | +69.25% | 3 | Mar 9, 2026 | |
| CALC CalciMedica | Maintains: Outperform | $20 → $10 | $0.6174 | +1,519.70% | 6 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $21 | $4.37 | +380.55% | 2 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $98 → $95 | $49.81 | +90.72% | 4 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $246 → $262 | $237.98 | +10.09% | 13 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $283 | $48.25 | +486.53% | 1 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $54 | $26.92 | +100.59% | 6 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $24 | $13.24 | +81.27% | 4 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $5.92 | +204.05% | 6 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $36 | $15.97 | +125.42% | 7 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $27.29 | +193.15% | 1 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $61 | $66.00 | -7.58% | 3 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $490 | $294.30 | +66.50% | 8 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $4.48 | +346.43% | 1 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $110 | $87.21 | +26.13% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $100 | $1.07 | +9,245.79% | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $135 → $147 | $207.78 | -29.25% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $26.29 | +101.60% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.55 | +238.03% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30,000 → $5,000 | $1.98 | +252,425.25% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $4.34 | +476.04% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $31.21 | -7.08% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $16.27 | +115.12% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 | $20.30 | +1,377.83% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $1.00 | +1,900.00% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $1.43 | +809.09% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $3.64 | +3,196.70% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $6.38 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $34.07 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $14.05 | - | 5 | Mar 31, 2020 |
Veru Inc.
May 15, 2026
Maintains: Outperform
Price Target: $25 → $24
Current: $2.11
Upside: +1,037.44%
Crinetics Pharmaceuticals
May 11, 2026
Maintains: Outperform
Price Target: $87 → $84
Current: $34.94
Upside: +140.41%
UroGen Pharma
May 7, 2026
Maintains: Outperform
Price Target: $34 → $40
Current: $28.26
Upside: +41.54%
Climb Bio
Apr 21, 2026
Maintains: Outperform
Price Target: $10 → $18
Current: $9.65
Upside: +86.53%
argenx SE
Apr 2, 2026
Maintains: Outperform
Price Target: $1,060 → $1,014
Current: $797.77
Upside: +27.10%
Soleno Therapeutics
Mar 18, 2026
Maintains: Outperform
Price Target: $110 → $80
Current: $53.01
Upside: +50.91%
enGene Therapeutics
Mar 11, 2026
Maintains: Outperform
Price Target: $33 → $30
Current: $1.53
Upside: +1,860.78%
Ocugen
Mar 11, 2026
Initiates: Outperform
Price Target: $10
Current: $1.30
Upside: +669.23%
Dianthus Therapeutics
Mar 9, 2026
Maintains: Outperform
Price Target: $125 → $145
Current: $85.67
Upside: +69.25%
CalciMedica
Mar 5, 2026
Maintains: Outperform
Price Target: $20 → $10
Current: $0.6174
Upside: +1,519.70%
Mar 2, 2026
Maintains: Outperform
Price Target: $35 → $21
Current: $4.37
Upside: +380.55%
Feb 24, 2026
Maintains: Outperform
Price Target: $98 → $95
Current: $49.81
Upside: +90.72%
Feb 12, 2026
Maintains: Outperform
Price Target: $246 → $262
Current: $237.98
Upside: +10.09%
Dec 23, 2025
Initiates: Outperform
Price Target: $283
Current: $48.25
Upside: +486.53%
Dec 8, 2025
Maintains: Outperform
Price Target: $22 → $54
Current: $26.92
Upside: +100.59%
Nov 14, 2025
Maintains: Outperform
Price Target: $23 → $24
Current: $13.24
Upside: +81.27%
Nov 7, 2025
Maintains: Outperform
Price Target: $18
Current: $5.92
Upside: +204.05%
Oct 21, 2025
Maintains: Outperform
Price Target: $32 → $36
Current: $15.97
Upside: +125.42%
Sep 3, 2025
Initiates: Outperform
Price Target: $80
Current: $27.29
Upside: +193.15%
Aug 6, 2025
Maintains: Outperform
Price Target: $60 → $61
Current: $66.00
Upside: -7.58%
Aug 4, 2025
Upgrades: Outperform
Price Target: $490
Current: $294.30
Upside: +66.50%
Jul 31, 2025
Initiates: Outperform
Price Target: $20
Current: $4.48
Upside: +346.43%
Jul 10, 2025
Maintains: Outperform
Price Target: $76 → $110
Current: $87.21
Upside: +26.13%
Mar 24, 2025
Initiates: Outperform
Price Target: $100
Current: $1.07
Upside: +9,245.79%
Nov 8, 2024
Maintains: Outperform
Price Target: $135 → $147
Current: $207.78
Upside: -29.25%
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $26.29
Upside: +101.60%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.55
Upside: +238.03%
Sep 3, 2024
Maintains: Outperform
Price Target: $30,000 → $5,000
Current: $1.98
Upside: +252,425.25%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $4.34
Upside: +476.04%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $31.21
Upside: -7.08%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $16.27
Upside: +115.12%
Apr 9, 2024
Maintains: Outperform
Price Target: $300
Current: $20.30
Upside: +1,377.83%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $1.00
Upside: +1,900.00%
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $1.43
Upside: +809.09%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $3.64
Upside: +3,196.70%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $6.38
Upside: -
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $34.07
Upside: -
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $14.05
Upside: -